Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Clinical trial NCT04729387 · TERMINATED
Trial details
- NCT number
- NCT04729387
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-22
- Primary completion
- 2023-04-21
- Enrollment
- 358
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.